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ity, it may still be helpful in diagnosing CMV colitis in some 
cases because of its high specificity.5 Although CMV infec-
tion has been reported as a risk factor for poor outcomes in 
two prospective multicenter studies by the IBD Study Group 
of the Korean Association for the Study for Intestinal Diseas-
es,7,8 there is little data concerning the relationship between 
CMV antigenemia assay results and clinical outcomes.
In the present study,9 the authors retrospectively evaluted 
the usefulness of the CMV antigenemia assay in predict-
ing clinical prognosis in UC patients in a single academic 
center. Of 146 patients hospitalized for an exacerbation of 
moderate-to-severe UC, 43 patients who had undergone 
the CMV antigenemia assay at the time of admission were 
included. Twelve of the patients had CMV antigenemia, and 
8 (66.7%) were diagnosed with CMV colitis by endoscopic 
biopsy. Of the 31 patients with negative CMV antigenemia 
assay results, 4 (12.9%) had CMV colitis. CMV antigenemia 
was significantly associated with CMV colitis (P=0.001). The 
sensitivity and specificity of the CMV antigenemia assay for 
CMV colitis were 66.7% and 87.1%, respectively. 
Regarding the clinical course, there was a significant as-
sociation between CMV antigenemia and refractoriness 
to corticosteroid therapy (P =0.002). Eleven of 12 (91.7%) 
patients in the CMV antigenemia-positive group, and 12 of 
31 (38.7%) patients in the CMV antigenemia-negative group 
had refractoriness. In addition, the titer of the antigenemia 
assay showed a tendency to be higher in patients with ste-
roid-refractory UC than in those with the steroid-responsive 
UC (P =0.058). Multivariate analysis revealed that steroid 
refractoriness was significantly increased in CMV antigen-
emia-positive patients (adjusted OR, 7.73; P =0.030), and in 
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EDITORIAL
Cytomegalovirus (CMV) is a pathogen implicated in a 
diverse spectrum of diseases, depending on the immune sta-
tus of the host. CMV usually leads to asymptomatic infection 
in immunocompetent individuals, but may cause serious 
morbidity and mortality in immunocompromised patients.1,2 
CMV is also considered to be the most common viral patho-
gen involved in IBD. CMV infection is frequently detected 
using colonic mucosal biopsy in severe cases of UC or CD, 
but its clinical significance is still controversial. CMV may be 
the cause of severe colitis flares, or may play the role of an in-
nocent bystander.3,4
Recently, noninvasive diagnostic methods such as the se-
rum CMV PCR and CMV antigenemia assay have received 
a lot of clinical interest owing to the difficulty in diagnosing 
CMV colitis. In a retrospective study by Kim et al., among 
229 moderate-to-severe UC patients, 83 patients (36.2%) 
had CMV colitis, and the sensitivity and specificity of the 
CMV antigenemia assay were found to be 47.0% and 81.7%, 
respectively.5 Jang et al. also reported similar results in 149 
patients with suspected CMV gastrointestinal disease, with 
the sensitivity and specificity of the CMV antigenemia assay 
being 54% and 88%, respectively.6 These results indicate that 
even though the CMV antigenemia assay could not replace 
endoscopic biopsy owing to its comparatively low sensitiv-
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patients with a shorter duration of UC (adjusted OR, 0.99; 
P=0.025). However, there was no significant difference in the 
colectomy rate between the positive group (33.3%) and the 
negative group (22.6%, P=0.467). In conclusion, the CMV an-
tigenemia assay showed low sensitivity but high specificity 
for detecting CMV colitis and predicting steroid-refractory 
UC.
There are some limitations to the present study. Selection 
bias may have been introduced when performing the CMV 
antigenemia assay, which could have influenced the results 
by leading to higher chances of testing CMV antigenemia 
in severe patients. Whether and when to examine for CMV 
colitis is generally decided by the attending physician, the se-
verity of the disease, and/or steroid refractoriness. In future 
studies, it would be beneficial to establish certain objective 
criteria for the CMV antigenemia assay, and to determine the 
optimal timing for blood sampling. Furthermore, the sample 
size was small, and the analysis was retrospective and based 
on medical charts, which makes it difficult to draw a con-
crete conclusion based on these results alone.
However, the present study clearly shows that CMV an-
tigenemia is an independent predictive factor for steroid 
refractoriness in moderate-to-severe cases of UC. Corticoste-
roid therapy is currently a significant tool in the management 
of acute exacerbation of UC. Moreover, a history of CMV has 
been shown to be predictive of nonresponse to infliximab.10 
CMV testing would be useful to predict the response to ste-
roids earlier in the treatment course. Therefore, testing for 
CMV should be routinely performed before corticosteroid or 
infliximab therapies in acute, severe cases of UC. However, 
a positive antigenemia test result is not sufficient to confirm 
a diagnosis of CMV colitis in cases of UC. It is generally ac-
cepted that sigmoidoscopy should be performed to both 
evaluate the disease status itself and determine if CMV infec-
tion is involved. Given that CMV antigenemia testing has a 
relatively high specificity as revealed by several studies, and 
that immunohistochemical staining of CMV takes 3−5 days 
before providing final results, the CMV antigenemia assay 
should be considered as a preliminary test in acute, severe 
cases of UC.
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